Aβ42 oligomer-specific antibody ALZ-201 reduces the neurotoxicity of Alzheimer’s disease brain extracts
Authors:
Open Access
- 29 December 2022
- journal article
- research article
- Published by Springer Nature in Alzheimer's Research & Therapy
- Vol. 14 (1) , 1-20
Abstract
Background: In Alzheimer’s disease (AD), amyloid-β 1–42 (Aβ42) neurotoxicity stems mostly from its soluble oligomeric aggregates. Studies of such aggregates have been hampered by the lack of oligomer-specific research tools and their intrinsic instability and heterogeneity. Here, we developed a monoclonal antibody with a unique oligomer-specific binding profile (ALZ-201) using oligomer-stabilising technology. Subsequently, we assessed the etiological relevance of the Aβ targeted by ALZ-201 on physiologically derived, toxic Aβ using extracts from post-mortem brains of AD patients and controls in primary mouse neuron cultures.Methods: Mice were immunised with stable oligomers derived from the Aβ42 peptide with A21C/A30C mutations (AβCC), and ALZ-201 was developed using hybridoma technology. Specificity for the oligomeric form of the Aβ42CC antigen and Aβ42 was confirmed using ELISA, and non-reactivity against plaques by immunohistochemistry (IHC). The antibody’s potential for cross-protective activity against pathological Aβ was evaluated in brain tissue samples from 10 individuals confirmed as AD (n=7) and non-AD (n=3) with IHC staining for Aβ and phosphorylated tau (p-Tau) aggregates. Brain extracts were prepared and immunodepleted using the positive control 4G8 antibody, ALZ-201 or an isotype control to ALZ-201. Fractions were biochemically characterised, and toxicity assays were performed in primary mouse neuronal cultures using automated high-content microscopy.Results: AD brain extracts proved to be more toxic than controls as demonstrated by neuronal loss and morphological determinants (e.g. synapse density and measures of neurite complexity). Immunodepletion using 4G8 reduced Aβ levels in both AD and control samples compared to ALZ-201 or the isotype control, which showed no significant difference. Importantly, despite the differential effect on the total Aβ content, the neuroprotective effects of 4G8 and ALZ-201 immunodepletion were similar, whereas the isotype control showed no effect.Conclusions: ALZ-201 depletes a toxic species in post-mortem AD brain extracts causing a positive physiological and protective impact on the integrity and morphology of mouse neurons. Its unique specificity indicates that a low-abundant, soluble Aβ42 oligomer may account for much of the neurotoxicity in AD. This critical attribute identifies the potential of ALZ-201 as a novel drug candidate for achieving a true, clinical therapeutic effect in AD.Keywords
This publication has 101 references indexed in Scilit:
- Increased in Vivo Amyloid-β42 Production, Exchange, and Loss in Presenilin Mutation CarriersScience Translational Medicine, 2013
- Ammonium hydroxide treatment of Aβ produces an aggregate free solution suitable for biophysical and cell culture characterizationPeerJ, 2013
- Amyloid-β Protein Oligomer at Low Nanomolar Concentrations Activates Microglia and Induces Microglial NeurotoxicityJournal of Biological Chemistry, 2011
- Decreased Clearance of CNS β-Amyloid in Alzheimer’s DiseaseScience, 2010
- Neurotoxicity of Alzheimer's disease Aβ peptides is induced by small changes in the Aβ42 to Aβ40 ratioThe EMBO Journal, 2010
- Stabilization of neurotoxic Alzheimer amyloid-β oligomers by protein engineeringProceedings of the National Academy of Sciences, 2010
- Days to criterion as an indicator of toxicity associated with human Alzheimer amyloid‐β oligomersAnnals of Neurology, 2010
- Structural conversion of neurotoxic amyloid-β1–42 oligomers to fibrilsNature Structural & Molecular Biology, 2010
- Amyloid-β protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memoryNature Medicine, 2008
- Neuropathological stageing of Alzheimer-related changesActa Neuropathologica, 1991